Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer

MT Newswires Live

Jan 10, 2025

Tyra Biosciences (TYRA) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.

The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.

TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.

Shares of the company were down nearly 5% in recent trading.

Price: 15.18, Change: -0.79, Percent Change: -4.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502951128"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502951128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502951128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 23:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502951128","market":"sg","top_or_hot":-1,"title":"Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer","media":"MT Newswires Live","content":"<html><body><p> Tyra Biosciences (TYRA) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.</p><p>The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.</p><p>TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.</p><p>Shares of the company were down nearly 5% in recent trading.</p><p>Price: 15.18, Change: -0.79, Percent Change: -4.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-10 23:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tyra Biosciences (TYRA) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.</p><p>The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.</p><p>TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.</p><p>Shares of the company were down nearly 5% in recent trading.</p><p>Price: 15.18, Change: -0.79, Percent Change: -4.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502951128","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502951128","pubTimestamp":1736524156,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tyra Biosciences  said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.Shares of the company were down nearly 5% in recent trading.Price: 15.18, Change: -0.79, Percent Change: -4.95","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TYRA":"Tyra Biosciences, Inc."},"translate_title":"Tyra Biosciences的TYRA-300获得美国FDA批准用于非肌层浸润性膀胱癌的2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYRA":1},"content_text":"Tyra Biosciences (TYRA) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer.The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly in the US. Patient dosing is expected to begin in Q2, followed by the initial three-month complete response data, which is the study's primary endpoint, the company said.TYRA-300 is also set to be evaluated in other phase 2 studies -- BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial carcinoma, the company added.Shares of the company were down nearly 5% in recent trading.Price: 15.18, Change: -0.79, Percent Change: -4.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}